Trial · NCT03732807
Results by group986
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 986
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 30.65 | 95% Confidence Interval 22.53 to 38.76 | Percentage of participants | |
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 22.31 | 95% Confidence Interval 14.90 to 29.73 | Percentage of participants | |
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Ritlecitinib (PF-06651600) 50 mg | 23.39 | 95% Confidence Interval 15.94 to 30.84 | Percentage of participants | |
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Ritlecitinib (PF-06651600) 30 mg | 14.29 | 95% Confidence Interval 8.00 to 20.57 | Percentage of participants | |
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Ritlecitinib (PF-06651600) 10 mg | 1.69 | 95% Confidence Interval 0.00 to 4.99 | Percentage of participants | |
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | Placebo | 1.54 | 95% Confidence Interval 0.00 to 3.65 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 21.29 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 12.87 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Ritlecitinib (PF-06651600) 50 mg | 13.42 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Ritlecitinib (PF-06651600) 30 mg | 10.62 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Ritlecitinib (PF-06651600) 10 mg | 1.65 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | Placebo | 1.54 | Percentage of participants | ||
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 21.77 | 95% Confidence Interval 14.51 to 29.04 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 13.22 | 95% Confidence Interval 7.19 to 19.26 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Ritlecitinib (PF-06651600) 50 mg | 13.71 | 95% Confidence Interval 7.66 to 19.76 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Ritlecitinib (PF-06651600) 30 mg | 10.92 | 95% Confidence Interval 5.32 to 16.53 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Ritlecitinib (PF-06651600) 10 mg | 1.69 | 95% Confidence Interval 0.00 to 4.99 | Percentage of participants | |
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | Placebo | 1.54 | 95% Confidence Interval 0.00 to 3.65 | Percentage of participants | |
| Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24 | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 52.19 | Percentage of participants | ||
| Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24 | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 45.40 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03732807/results